Recombinant (Rhesus macaque) Ly-6/neurotoxin-like protein 1 (LYNX1); Ly-6/neurotoxin-like protein 1

For Research Use Only. Not for use in diagnostic procedures.

Chromosome: 8; NC_007865.1 (145314498..145315475, complement). Location: chromosome: 8

E Coli or Yeast or Baculovirus or Mammalian Cell

>=90% (lot specific)

Liquid containing glycerol

This protein contains an N-terminal tag and may also contain a C-terminal tag. Tag types are determined by various factors including tag-protein stability, please inquire for tag information.

Sterile filter available upon request.

Low endotoxin available upon request.

Store at -20 degree C. For extended storage, store at -20 or -80 degree C.

Manufactured in an ISO 13485:2003 and EN ISO 13485:2012 Certified Laboratory.

Small volumes of LYNX1 recombinant protein vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

14,090 Da[Similar Products]

ly-6/neurotoxin-like protein 1; Ly-6 neurotoxin-like protein 1

Ly-6/neurotoxin-like protein 1

LYNX1_MACMU

Function: Acts in different tissues through interaction to nicotinic acetylcholine receptors (nAChRs). Isoforms 2/4 modulates functional properties of nicotinic acetylcholine receptors (nAChRs) to prevent excessive excitation, and hence neurodegeneration. Enhances desensitization by increasing both the rate and extent of desensitization of alpha4beta2 nAChRs and slowing recovery from desensitization. Promotes large amplitude ACh-evoked currents through alpha4beta2 nAChRs

By similarity. Prevents plasticity in the primary visual cortex late in life

By similarity. In keratinocytes, isoform 3 delays differentiation and prevents apoptosis

By similarity.

Subunit structure: Interacts with nAChRs, including alpha4beta2 (CHRNA4/CHRNB2) and alpha7 (CHRNA7)

By similarity.

Subcellular location: Isoform 1: Secreted

Potential Ref.1. Isoform 2: Cell membrane; Lipid-anchor ? GPI-anchor

Potential Ref.1. Cell projection ? dendrite

By similarity. Note: Detected in Purkinje cells soma and proximal dendrites

By similarity. Colocalizes with different types of nAChRs. Ref.1Isoform 3: Secreted

By similarity Ref.1. Isoform 4: Cell membrane; Lipid-anchor ? GPI-anchor

Potential Ref.1.

Tissue specificity: Expressed in brain. Isoforms 2/4 expressed in lung. In the lung, expressed predominantly in airway epithelial cells, submucous glands, and smooth muscle cells, in endothelial and smooth muscle cells in vessel walls and in alveolar type II cells (at protein level). Ref.1

Developmental stage: Detected as early as day 71 of gestation. Expression increases consistently in lungs throughout the prenatal period. After birth, expression continues well into *****hood. At 71 days of gestation (pseudoglandular phase), expression is detected in tracheal and proximal conducting airway epithelium. Expression decreases gradually toward the distal airways. Strong expression in the epithelium lining the tips of the dichotomous and monopodial airway buds. Weakly expressed in smooth muscle cells around the large airways. Weakly expressed in mesenchymal cells and not at all in the mesenchymal cells surrounding the airway buds. Not detected in vessels associated with large airways (at protein level). At 94 days of gestation, similar expression pattern, but expression increases and extends toward distal airway epithelium. Strong expression in type II cells that line the primitive air spaces of late canalicular and early saccular phase. More prominent expression in the smooth muscle cells surrounding the large airways. Begins to be weakly expressed in endothelial and smooth muscle cells in large vessels, but not in small distal vessels (at protein level). At day 134 of gestation, further increase in expression in the distal airway epithelium. In large airways, predominantly expressed in the ciliated epithelium. Expressed at low levels in the mucus-secreting cells and at high levels in the submucosal gland cells. Weakly expressed in paracartilaginous cells, but not in cells in the extra-cartilaginous layer. Not detected in type I alveolar cells. Strongly expressed in endothelial and smooth muscle cells increased in large vessels and in distal vessels (at protein level). At birth, similar pattern of expression. Slightly decreased expression in the proximal airways (at protein level). Ref.1

Induction: Up-regulated by prenatal nicotine exposure. Ref.1

Sequence similarities: Contains 1 UPAR/Ly6 domain.

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.